Contributions
Abstract: PB2127
Type: Publication Only
Background
Anemia is a common complication of patients with hematological malignancies (HM), which may progress undergoing antitumor treatment significantly decreasing hemoglobin concentration and occur symptoms as fatigue, dizziness, palpitations, dyspnea markedly reduce patient activity, resulting in impaired Quality of Life (QoL).
Aims
To compare of QoL in HM's patients with different grades of anemia.
Methods
In this study were included following patients (n=326) in the age of 19-82 (Me=65) years: myelodysplastic syndrome (n=37), acute myeloid leukemia (n=20), acute lymphoid leukemia (n=7), primary myelofibrosis (n=23), chronic myeloid leukemia in blast crisis (n=6), multiple myeloma in II and III st. (n=126), Non-Hodgkin's lymphoma in III-IV st. (n=40) and chronic lymphocytic leukemia in B or C st. (n=67). Patients were examined: 1) clinical blood test (hemoglobin concentration) to assess anemia’s grade; 2) the Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale to measure of QoL. The FACT-An questionnaire consists of a general questionnaire (FACT-G), measuring domains of physical well-being (PW), social/family well-being (S/FW), emotional well-being (EW), functional well-being (FW), an anemia-specific questionnaire – Anemia subscale (AnS), measuring fatigue-associated items – Fatigue subscale (FS) and non-fatigue-associated items – Non-Fatigue subscale (NFS). Patients were divided into six groups according to the Hb concentration: 1) the first group – Hb was 4.0-6.4 g/dl (Me=5.7 g/dl); 2) the second – Hb 6.5-7.9 g/dl (Me=7.2 g/dl); the third – Hb 8.0-9.4 g/dl (Me=8.6 g/dl); the forth – Hb 9.5-10.9 g/dl (Me=10.8 g/dl); the fifth – Hb 11.0-11.9 g/dl (Me=11.4 g/dl); the sixth – Hb 12.0-14.4 g/dl (Me=13.0 g/dl). The sixth group was control.
Results
In the first group of patients (n=34) with severe anemia grade 4 QoL was revealed too poor; number of points in the subscale of PW was 14.0±0.9, in S/FW – 14.2±0.7; EW – 10.3±0.9, FW – 18.5±0.8, AnS – 41.2±1.6, FS – 27.8±1.3, NFS – 13.4±0.6. In the second group of patients (n=53) with anemia grade 3 QoL was poor too; in PW was 13.3±0.8, in S/FW – 14.4±0.6, EW – 9.9±0.7, FW – 18.2±0.6, AnS – 38.5±2.3, FS – 26.8±1.7, NFS – 12.0±0.7. In the third group of patients (n=72) with anemia grade 2 QoL in the subscale of PW was 11.5±0.7, in S/FW – 14.0±0.5, EW – 8.6±0.6, FW – 16.9±0.5, AnS – 36.1±1.9, FS – 25.5±1.4, NFS – 11.6±0.6. In the forth group of patients (n=70) with anemia grade 1 QoL in PW was 11.3±0.7, in S/FW – 14.3±0.6, EW – 8.4±0.8, FW – 16.9±0.7, AnS – 34.7±1.6, FS – 23.0±1.2, NFS – 11.7±0.6. In the fifth group of patients (n=41) with anemia grade 0 QoL in PW was 11.1±0.9, in S/FW – 14.9±0.8, EW – 7.6±0.6, FW – 16.4±0.5, AnS – 34.6±2.2, FS – 23.7±1.6, NFS – 10.9±0.7. In the sixth group of patients (n=56) without anemia QoL in the subscale of PW was 7.5±0.7, in S/FW – 13.6±0.6, EW – 6.4±0.5, FW – 14.8±0.7, AnS – 23.4±1.5, FS – 14.9±1.0, NFS – 8.4±0.6.
Conclusion
QoL was found too poor in patients with Hb <8.0 g/dl. QoL wasn't satisfactory in patients with Hb 8.0-11.0 g/dl. But the QoL improvement were greater in patients with Hb levels >11.0-12.0 g/dl (p<0.05). These data suggest that early correct anemia with red blood sells transfusions and erythropoiesis-stimulating agents can improve QoL in a clinically meaningful way.
Session topic: 35. Quality of life, palliative care, ethics and health economics
Keyword(s): Quality of Life, Hemoglobin, Hematological malignancy, Anemia
Abstract: PB2127
Type: Publication Only
Background
Anemia is a common complication of patients with hematological malignancies (HM), which may progress undergoing antitumor treatment significantly decreasing hemoglobin concentration and occur symptoms as fatigue, dizziness, palpitations, dyspnea markedly reduce patient activity, resulting in impaired Quality of Life (QoL).
Aims
To compare of QoL in HM's patients with different grades of anemia.
Methods
In this study were included following patients (n=326) in the age of 19-82 (Me=65) years: myelodysplastic syndrome (n=37), acute myeloid leukemia (n=20), acute lymphoid leukemia (n=7), primary myelofibrosis (n=23), chronic myeloid leukemia in blast crisis (n=6), multiple myeloma in II and III st. (n=126), Non-Hodgkin's lymphoma in III-IV st. (n=40) and chronic lymphocytic leukemia in B or C st. (n=67). Patients were examined: 1) clinical blood test (hemoglobin concentration) to assess anemia’s grade; 2) the Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale to measure of QoL. The FACT-An questionnaire consists of a general questionnaire (FACT-G), measuring domains of physical well-being (PW), social/family well-being (S/FW), emotional well-being (EW), functional well-being (FW), an anemia-specific questionnaire – Anemia subscale (AnS), measuring fatigue-associated items – Fatigue subscale (FS) and non-fatigue-associated items – Non-Fatigue subscale (NFS). Patients were divided into six groups according to the Hb concentration: 1) the first group – Hb was 4.0-6.4 g/dl (Me=5.7 g/dl); 2) the second – Hb 6.5-7.9 g/dl (Me=7.2 g/dl); the third – Hb 8.0-9.4 g/dl (Me=8.6 g/dl); the forth – Hb 9.5-10.9 g/dl (Me=10.8 g/dl); the fifth – Hb 11.0-11.9 g/dl (Me=11.4 g/dl); the sixth – Hb 12.0-14.4 g/dl (Me=13.0 g/dl). The sixth group was control.
Results
In the first group of patients (n=34) with severe anemia grade 4 QoL was revealed too poor; number of points in the subscale of PW was 14.0±0.9, in S/FW – 14.2±0.7; EW – 10.3±0.9, FW – 18.5±0.8, AnS – 41.2±1.6, FS – 27.8±1.3, NFS – 13.4±0.6. In the second group of patients (n=53) with anemia grade 3 QoL was poor too; in PW was 13.3±0.8, in S/FW – 14.4±0.6, EW – 9.9±0.7, FW – 18.2±0.6, AnS – 38.5±2.3, FS – 26.8±1.7, NFS – 12.0±0.7. In the third group of patients (n=72) with anemia grade 2 QoL in the subscale of PW was 11.5±0.7, in S/FW – 14.0±0.5, EW – 8.6±0.6, FW – 16.9±0.5, AnS – 36.1±1.9, FS – 25.5±1.4, NFS – 11.6±0.6. In the forth group of patients (n=70) with anemia grade 1 QoL in PW was 11.3±0.7, in S/FW – 14.3±0.6, EW – 8.4±0.8, FW – 16.9±0.7, AnS – 34.7±1.6, FS – 23.0±1.2, NFS – 11.7±0.6. In the fifth group of patients (n=41) with anemia grade 0 QoL in PW was 11.1±0.9, in S/FW – 14.9±0.8, EW – 7.6±0.6, FW – 16.4±0.5, AnS – 34.6±2.2, FS – 23.7±1.6, NFS – 10.9±0.7. In the sixth group of patients (n=56) without anemia QoL in the subscale of PW was 7.5±0.7, in S/FW – 13.6±0.6, EW – 6.4±0.5, FW – 14.8±0.7, AnS – 23.4±1.5, FS – 14.9±1.0, NFS – 8.4±0.6.
Conclusion
QoL was found too poor in patients with Hb <8.0 g/dl. QoL wasn't satisfactory in patients with Hb 8.0-11.0 g/dl. But the QoL improvement were greater in patients with Hb levels >11.0-12.0 g/dl (p<0.05). These data suggest that early correct anemia with red blood sells transfusions and erythropoiesis-stimulating agents can improve QoL in a clinically meaningful way.
Session topic: 35. Quality of life, palliative care, ethics and health economics
Keyword(s): Quality of Life, Hemoglobin, Hematological malignancy, Anemia